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Abstract We here describe that soluble HLA-DQ2 (sDQ2)
molecules, when expressed in Drosophila melanogaster S2
insect cells without a covalently tethered peptide, associate
tightly with the D. melanogaster calcium binding protein
DCB-45. The interaction between the proteins is stable in S2
cell culture and during affinity purification, which is done at
high salt concentrations and pH 11.5. After affinity purifica-
tion, the sDQ2/DCB-45 complex exists in substantial
quantities next to a small amount of free heterodimeric
sDQ2 and large amounts of aggregated sDQ2 free of DCB-
45. Motivated by the stable complex formation and our
interest in the development of reagents which inhibit HLA-
DQ2 peptide binding, we have further characterized the
sDQ2/DCB-45 interaction. Several lines of evidence indicate
that an N-terminal fragment of DCB-45 is involved in the
interaction with the peptide binding groove of sDQ2. Further
mapping of this fragment of 54 residues identified a
pentadecapeptide with high affinity for sDQ2 which may
serve as a lead compound for the design of HLA-DQ2
blockers.
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Introduction
HLA-DQ2 (DQA1*0501/DQB1*0201) is associated with
several immune-mediated disorders including celiac disease
(Sollid et al. 1989; Thorsby and Ronningen 1993; Todd et
al. 1987). In order to develop specific blockers as a
potential future treatment for celiac disease and other
HLA-DQ2 associated diseases, there is a need to define
high affinity ligands for HLA-DQ2. The development of
such blockers will be facilitated by the production of
recombinant HLA-DQ2 that can be made in high quantities
and utilized for binding studies. On this background, we
have produced recombinant, soluble HLA-DQ2 (sDQ2)
molecules in either stably transfected S2 cells or in
baculovirus infected Sf9 cells. Interestingly, when express-
ing sDQ2 in S2 cells without a covalently bound peptide
that occupies the binding groove, we obtained remarkably
high amounts of stable molecules. Further analysis of these
sDQ2 molecules revealed that a major proportion of the
molecules copurifies with the Drosophila melanogaster
calcium binding protein DCB-45, a homolog to the D.
melanogaster supercoiling factor (SCF; Kobayashi et al.
1998). Given the apparent ability of the protein to stabilize
sDQ2, we hypothesized that it could contain a peptide
which binds efficiently to the binding groove of sDQ2 and
which could function as a lead peptide for the development
of HLA-DQ2 blockers. Here, we report on the identifica-
tion and characterization of the DCB-45 sequence which
mediates binding to sDQ2. Next to characterizing the
interaction between sDQ2 and DCB-45, our observations
are of general relevance for expression of recombinant
major histocompatibility complex (MHC) class II mole-
cules in S2 cells.
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Materials and methods
HLA expression and purification
Water soluble HLA-DQ2 (DQA1*0501/DQB1*0201) was
expressed in a D. melanogaster S2 cell line by cotransfec-
tion of three vectors: a pMtal vector with the sequence
encoding for the extracellular part of the DQα-chain fused
to the Fos zipper, a pMtal vector with the sequence
encoding the extracellular part of the DQβ-chain fused to
the Jun zipper, and a pCoHYGRO resistance vector
(Paulsen et al., unpublished). The construct did not include
a sequence for a high affinity peptide ligand tethered to the
β-chain. The stably transfected S2 cells were grown in 1L
cell spin flasks at 22°C in serum-free media (Insect-
XPRESS™, BioWhittaker, Walkersville, MD, USA), con-
taining 300 μg/ml hygromycin B (Invitrogen, Carlsbad,
CA, USA) and 25 μg/ml garamycin (Schering-Plough,
Kenilworth, NJ, USA). The pMtal vectors contain a metal-
lothionein promoter and the production of sDQ2 was
induced by 100 mM CuSO4 over 3 days. From cell culture
supernatants, the sDQ2 molecules were affinity-purified like
previously described (Quarsten et al. 2001). HLA-DM
molecules were produced as soluble molecules in transfected
S2 cells (kind gift of Elizabeth Mellins) and purified by
FLAG-tag immunoaffinity chromatography and size exclu-
sion chromatography as described (Sloan et al. 1995).
Detergent-solubilized HLA-DQ2 (DQA1*0501/DQB1*0201;
EBV-DQ2) molecules were purified from Epstein–Barr virus-
transformed B lymphoblastoid cell lines as previously
described (Johansen et al. 1994). The protein concentration
of the various HLA molecules was determined by a BCA
protein assay kit (Pierce, Rockford, IL, USA).
Size exclusion chromatography and gel electrophoresis
Preparative size exclusion chromatography was performed
on an Äkta purifier system (Amersham Biosciences Corp.,
Piscataway, NJ, USA) using a Superdex 200 10/300 GL
column (Amersham Bioscience). Proteins were separated by
isocratic elution (flow rate 0.75 ml/min) using phosphate
buffered saline (PBS; pH 7.3) and monitored at 280 nm.
One-dimensional sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed using 6–12%
polyacrylamide gels. Samples were reduced by heating in
Laemmli buffer containing 1% β-mercaptoethanol (95°C,
5 min). Proteins were stained by Coomassie Blue.
Trypsin treatment
For protein identification by peptide mass fingerprinting,
protein bands were excised from the Coomassie Blue
stained gel and in-gel digested as previously described
(Fleckenstein et al. 2004). For the acetylation of primary
amino groups, the gel pieces were incubated in 3%
acetanhydride/0.1 M NaHCO3 pH 8.4 for 2 h at room
temperature, followed by several washing steps and tryptic
digestion. Partial digestion of the sDQ2/DCB-45 complex
in solution was performed with N-tosyl L-phenylalanyl
chloromethyl ketone (TPCK) trypsin agarose beads
(Pierce). For 24 μg protein, 4.8 μl bead suspension in
0.1 M NH4HCO3 buffer in a total volume of 22.8 μl was
used. The samples were incubated for 17 min at 37°C under
rotation. For size exclusion chromatography, the beads were
removed by filtration.
Mass spectrometry
Matrix-assisted laser desorption–ionization time-of-flight
mass spectra (MALDI-TOF MS) were acquired on a
MALDI-TOF/TOF instrument (Ultraflex II, Bruker Daltonics,
Bremen, Germany). Tryptic peptide mixtures and peptides
eluted from sDQ2were desalted and concentrated on Poros 20
R2 reverse-phase packing sorbent (Applied Biosystems,
Foster City, CA, USA) packed in 20-μl GELoader tips
(Eppendorf, Hamburg, Germany). Peptides were eluted onto
a stainless steel target plate using 70% acetonitrile, containing
0.1% trifluoroacetic acid (TFA) and 10 g/l α-cyano-4-
hydroxycinnamic acid. Synthetic peptides were also analyzed
using α-cyano-4-hydroxycinnamic acid, but then samples
were applied as a dried droplet.
Peptide synthesis
Peptides with a length of 11–20 amino acid residues were
synthesized on Rink amid methylbenzhydrylamine-resin
using Fmoc/2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyl-
uronium hexafluorophosphate (HBTU) chemistry and a
pipetting robot (Syro I, MultiSynTech, Bochum, Germany).
Coupling was performed with a tenfold molar excess of
each Fmoc-L-amino acid and HBTU and a 15-fold excess
of N,N-diisopropylethylamine. Piperidine (20% in dime-
thylformamide) was used for Fmoc deprotection and 96%
TFA containing 2% triisopropylsilane and 2% water were
used for side chain deprotection and cleavage from the
resin. The identity was confirmed by MALDI-TOF MS,
and the purity was determined by analytical reversed-phase
high performance liquid chromatography (HPLC; Agilent
1100 system, Agilent Technologies, Santa Clara, CA, USA)
using a Zorbax C18 column (Agilent Technologies). The 54
residue long peptide was synthesized on 10 mg NovaPEG
Rink Amide resin LL (Novabiochem®, Merck KGaA,
Darmstadt, Germany) with a low loading capacity of
0.16 mmol/g. The pseudoproline dipeptides Fmoc-Gly-
(Hmb)Gly-OH (Novabiochem) in position 24 and Fmoc-
Glu(OtBu)-Ser(ψMe,Mepro)-OH (Novabiochem) in position
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41 and 52 were used to substitute for Gly-Gly and Glu-Ser,
respectively. The secondary amide bond of these amino
acid surrogates is reversibly protected and cleaved during
deprotection with 96% TFA. The first 30 cycles were run
under standard conditions as described above. From
cycle 30 on, all coupling steps were repeated and 30%
piperidine in dimethylformamide for Fmoc deprotection
was used. Side chain deprotection and cleavage from the
resin was performed as described above. From the crude
peptide, the observed TFA ester on the N-terminal Ser side
chain was removed by treatment with 1 M NaOH for
30 min, followed by neutralization with equimolar amounts
of HCl. The identity and purity were determined like
described above.
Labeling of synthetic peptides
The HLA-DQ2 high affinity ligand P198 (KPLLIIAEDVE-
GEY, Mycobacterium bovis 65 kDa Hsp 243–255Y) was
either fluorescently labeled or radiolabeled. The radio-
labeling with 125I was done with the chloramine T method
(Greenwood et al. 1963). Fluorescence labeling was done
by N-terminally coupling of 5(6)-carboxyfluorescein (CF)
using 5 equivalents CF and 6 equivalents N,N-diisopropyl-
carbodiimide. The coupling step was repeated several times
until a negative Kaisertest was obtained (Kaiser et al.
1970). The fluorescently labeled peptide was cleaved from
the resin and analyzed as described above.
Peptide binding assays
Detergent-solubilized HLA-DQ2 (DQA1*0501/DQB1*0201;
EBV-DQ2) at concentrations of 0.1–0.2 μM was incubated
with the radioactively labeled P198 indicator peptide and
synthetic peptides at various concentrations as described earlier
(Johansen et al. 1994). The EBV-DQ2-peptide complexes
were subsequently separated from unbound peptides by size
exclusion chromatography in a spin column system as
described (Buus et al. 1995). The radioactivity in the void
volume and in the column material was counted by a γ-
counter (Wallac, Turku, Finland) and IC50 values were
calculated. sDQ2 (6.25 μM) or trypsin digested sDQ2
(6.25 μM) was incubated with CF-labeled P198 indicator
peptide (10 μM). In some instances, soluble HLA-DM
(sDM) was added in a concentration of 0.38 μM. The
incubation was performed in a total volume of 13 μl of a
citrate phosphate buffer (pH 5.3) at 37°C over 48 h. Next,
5 μl of each sample were transferred on a Zorbax GF 450
4.9×250-mm column and eluted with 150 mM PBS at a flow
rate of 1 ml/min using an Agilent 1100 HPLC system. The
UV signal (214 nm) and the fluorescence signal (Ex. 490 nm,
Em. 520 nm) were monitored. Peptide binding to sDQ2 was
quantified by measuring the area under the curve (AUC) of
the fluorescence signal for peaks with a maximum between
9.5 and 9.7 min (corresponding to sDQ2 with bound indicator
peptide). The mean values from at least two independent
experiments were plotted.
Results
Characterization of the sDQ2 preparation by SDS-PAGE
and size exclusion chromatography
The affinity purified sDQ2 was analyzed by SDS-PAGE
under reducing conditions. In addition to the bands of 35 and
25 kDa corresponding to the sDQ2 α- and β-chains,
respectively, a protein with an approximate molecular weight
of 50 kDa was observed (Fig. 1A). In size exclusion
chromatography under nonreducing conditions, the same
sample eluted in three peaks, which were fractionated for
further analysis by SDS-PAGE (Fig. 1B,C). As the first peak
eluted with the void volume, we consider it to represent
aggregates of sDQ2 with a size larger than 600 kDa. SDS-
PAGE analysis of this fraction (Fig. 1C, lanes a and e)
showed the presence of sDQ2 α- and β-chains, but no band
at 50 kDa. In the second fraction (Fig. 1C, lanes b and f), the
50-kDa protein was detected with similar intensity as the
sDQ2 α- and β-chains. Peak 3 mainly contains sDQ2 α- and
β-chain (Fig. 1C, lane c). The small amount of the 50-kDa
protein can be explained by the overlap of peak 2 and 3 and
the small amounts of peak 2 present in fraction 3. The
amount of protein applied to each lane of the SDS-PAGE
was calculated by combining the known amount of total
protein subjected to size exclusion chromatography and by
determination of the peak areas for each of the fractions 1–3.
This was 2.2 μg for each of the lanes a–c. For the lanes e
and f, 29 μg of protein of the fractions 1 and 2, respectively,
was loaded in each lane. The protein bands in the lanes a and
e (corresponding to fraction 1) appeared weaker compared to
the protein bands detected in the lanes b and f
(corresponding to fraction 2), although identical amount of
protein should have been loaded. This might be due to
aggregation of sDQ2 in fraction 1, leading to an incomplete
transfer into the gel.
Identification of the 50-kDa protein by peptide mass
fingerprinting
In order to identify the nature of the 50-kDa contamination,
the protein was subjected to tryptic in-gel digestion. The
digest was analyzed on a MALDI-TOF/TOF mass spec-
trometer and a MASCOT search reported the identification
of a D. melanogaster-derived SCF (accession number
Q9W0H8_DROME). Acetylation prior to digestion and
analysis by MALDI-TOF/TOF MS identified the tryptic
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peptide SSIPEELPHNPLEHDPLHPR as the N terminus of
the protein. The observed 50-kDa protein therefore repre-
sents a N-terminally truncated derivate of the D. mela-
nogaster calcium binding protein (DCB-45), which is
described as an elongated homolog of SCF (Kobayashi et
al. 1998). The identified protein is highly acidic with a pI of
4.27.
Limited digestion of sDQ2/DCB-45 complexes
To investigate the interaction between DCB-45 and sDQ2,
we subjected the obtained sDQ2 preparation to limited
tryptic digestion with immobilized TPCK trypsin. As
evaluated by SDS-PAGE, a digestion time of 17 min at
37°C was found to be optimal to fully degrade DCB-45
Fig. 2 Limited tryptic digestion
of the purified sDQ2 preparation
analyzed by SDS-PAGE (A) and
size exclusion chromatography
(B). B Overlay of the size
exclusion chromatograms of the
nondigested (broken line) and
trypsin treated sDQ2 preparation
(full line)
Fig. 1 Analysis of sDQ2 produced in S2 insect cells by reducing
SDS-PAGE (A, C) and size exclusion chromatography (B). A SDS-
PAGE of the purified sDQ2 preparation. B Analysis and fractionation
of the produced sDQ2 by size exclusion chromatography. C The three
fractions obtained in B were reanalyzed by SDS-PAGE. Lanes a–c,
fractions 1, 2 and 3, respectively (2.2-μg protein loaded); lane d,
molecular weight standard (BIO-RAD, precision plus protein™
standard); lane e and f, fraction 1 and 2, respectively (29 μg protein
loaded). Amounts of protein loaded onto the gel were calculated from
the known amount of total protein subjected to size exclusion
chromatography and determination of the peak area
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(Fig. 2A). Under these conditions, the sDQ2 α-chain
remains intact whereas most of the β-chain undergoes a
small truncation which does not interfere with formation of
a stable and functional heterodimer (see below). Size
exclusion chromatography of the same digested sample
demonstrated a complete disappearance of the sDQ2/DCB-
45 complex which eluted in peak 2 of the untreated sample
(Fig. 2B). Notably, the limited proteolysis resulted in a
significant increase of the signal intensity observed for peak
3. Following purification of peak 3, the sDQ2 in this
preparation was found to be stable for at least 2 days when
coincubated at 37°C not only with the high affinity HLA-
DQ2 binding peptide P198 but also without adding peptide
for at least 24 h at 4°C (data not shown). This suggests that
sDQ2 in the partly digested sample remains as a stable
heterodimer with an occupied and thereby stabilized
peptide binding groove. Peak 3 of the trypsin-treated
sDQ2 preparation (Fig. 2B) was concentrated over a
10-kDa spin filter (Vivaspin), washed with PBS, and
treated with 0.1% TFA to elute ligands occupying the
peptide binding groove. Analysis of the eluted peptides by
MALDI-TOF/TOF MS identified four tryptic peptides
which were all derived from the 54 N-terminal amino acid
sequence of DCB-45 (Fig. 3). These peptides share a 23
amino acid long core sequence (HFDGGEHNAQFD
HEAFLGPDESK), suggesting the interaction site is within
this region. Besides the DCB-45-derived peptides, we
found low signal intensities for several other peptides in
the MALDI-TOF spectrum. One of these peptides could be
identified as STEFSEDLLDEDLDLSDIDENEEEFLR, and
this fragment is derived from the D. melanogaster protein
RH45818p (Fig. 3).
Peptide binding ability of sDQ2/DCB-45 before
and after limited tryptic digestion
The sDQ2/DCB-45 complex (i.e., peak 2 in Fig. 2B, broken
line) was purified, and its peptide binding ability was
analyzed using the fluorescence-labeled HLA-DQ2 high
affinity ligand P198. Peptide binding to sDQ2/DCB-45 was
found to be poor, and also limited tryptic digestion of the
complex could only slightly increase binding of P198
(Fig. 4). In the presence of HLA-DM, however, binding of
P198 was remarkably increased, both for the trypsin treated
and untreated sDQ2/DCB-45.
Identification of the HLA-DQ2 peptide binding frame
and binding affinity of DCB-45-derived peptides
To further investigate whether the interaction between
DCB-45 and sDQ2 is involving the peptide binding groove,
we synthesized five 20-mer peptides with overlapping
sequences which covered the 54 amino acid long N-
terminal DCB-45 sequence (Table 1). The peptide binding
affinity was tested in the competition assay using the 125I-
labeled indicator peptide P198 and EBV-DQ2. In this assay,
the highest affinity was found for the 20-mer
PRHFDGGEHNAQFDHEAFLG. To identify the exact
binding frame, three 15-mer peptides covering this 20-mer
region were synthesized and tested. The best binding
sequence was found to be HNAQFDHEAFLGPDE with
an IC50 of 0.13 μM. The truncated peptide HNAQFD-
HEAFL also bound with a good affinity (0.77 μM),
suggesting AQFDHEAFL as the 9-mer core region medi-
ating HLA-DQ2 binding (Table 1). The IC50 value of the
Fig. 3 MALDI-TOF mass spectrum of acid-eluted peptides after
trypsin treatment and fractionation of the heterodimeric sDQ2 fraction
(peak 3; Fig. 2B). The sequences of the five peptides assigned by their
m/z values were determined by MALDI-TOF/TOF MS and are given
in the insert. Four of the identified peptides derive from DCB-45. The
9-mer, suggested as the core region interacting with the HLA-DQ2
peptide binding groove, is shown in bold face
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54-mer is higher than that of the best binding pentadeca-
peptide (Table 1), what can obviously not be explained by
the slightly lower purity of the 54-mer (72%). Likely, a
different secondary structure of the longer peptide hinders
the interaction with the peptide binding groove resulting in
the observed lower binding affinity.
Peptide binding specificity of sDQ2 compared to EBV-DQ2
The α-I-gliadin epitope and analogs were tested for binding
to sDQ2 and EBV-DQ2. For both DQ2 molecules, the
calculated relative binding capacity and the ranking of the
measured IC50 values for the set of peptides was found to
be nearly identical. This strongly indicates that the peptide
binding specificity of sDQ2 matches that of EBV-DQ2
(Fig. 5).
Discussion
In this study, we show that soluble HLA-DQ2 molecules
without a covalently tethered peptide ligand copurify with
the D. melanogaster-derived protein DCB-45, when
expressed in S2 insect cells. We identified the fragment of
DCB-45 which mediates the strong interaction with sDQ2
and obtained evidence indicating that a part of this fragment
is binding to the sDQ2 binding groove with high affinity.
The sDQ2 stabilizing effect of the DCB-45 protein
motivated us to unravel the basis for this interaction as
Fig. 4 Binding of the HLA-DQ2 high affinity ligand P198 to sDQ2/
DCB-45. Carboxyfluorescein-labeled P198 was incubated with the
purified sDQ2/DCB-45 complex with or without prior limited tryptic
digestion and in the presence or absence of soluble HLA-DM (sDM).
Binding was quantified in a gel-filtration assay and is given by the
fluorescence signal (AUC) measured for the sDQ2/DCB-45 complex
(undigested sample) or sDQ2 after limited digestion (digested
sample). The signals were observed at an elution time of 9.5–
9.7 min. Values were obtained from at least two independent
experiments; mean and standard errors are shown
















IC50 is the peptide concentration required to give 50% inhibition of the binding of the indicator peptide (P198). The IC50 values for the peptides
presented in this table were analyzed in two separate sets of experiments. The results from one of three consistent titrations are given. As a
reference peptide, P198 (KPLLIIAEDVGEY) was included. The HLA-DQ2 binding frames are indicated in bold face
a In the first set of experiments, the binding affinity of the 54-mer peptide (72% pure) compared to gliadin-derived peptides P1269 (HLA-DQ2-α-I
epitope; QLQPFPQPELPY), P1274 (HLA-DQ2-α-II epitope PQPELPYPQPQLPY) and indicator peptide P198 was analyzed
b In the second set of experiments, the binding of overlapping synthetic peptides spanning the 54 amino acid long N-terminal region of DCB-45
was analyzed
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part of an effort to design compounds that can block HLA-
DQ2-mediated antigen presentation.
Expression of HLA class II molecules in insect cells is a
commonly used method for the production of recombinant
molecules (De Wall et al. 2006; Stern and Wiley 1992;
Wallny et al. 1995). Initially, DR1 and other MHC class II
molecules were expressed without a covalently tethered
peptide as so called “empty” class II molecules (Stern and
Wiley 1992). The expression of recombinant molecules
with a high affinity ligand covalently tethered to the N
terminus of the β-chain (Crawford et al. 1998), however,
gave improved expression and stable molecules and this
strategy thus developed as a preferred expression modality.
Our early work to express sDQ2 without a covalently
tethered peptide in the S2 cell system gave unusually high
protein yields and stable molecules what is in contrast to a
poor expression yield and unstable molecules obtained with
similar baculoviral constructs in Sf9 cells (Quarsten et al.,
unpublished). When analyzing and comparing peptide
binding specificity of these sDQ2 molecules with deter-
gent-solubilized HLA-DQ2 purified from EBV-transformed
B cells (EBV-DQ2), we found the same peptide binding
preferences but approximately a tenfold increase of the
IC50 values for each peptide when using the sDQ2
molecules (Fig. 5).
In mammalian antigen presenting cells the assembly of
HLA class II α- and β-chains is dependent on the invariant
chain (Ii) protein. In the ER, Ii is protecting and stabilizing
the class II binding groove with its class II-associated
invariant chain peptide (CLIP) sequence, and the Ii is
directing the class II molecules to the late endosomes where
HLA-DM catalyzes the exchange of CLIP for antigenic
peptides (Busch et al. 2005; Cresswell 1994). In S2 cells,
this mechanism for sDQ2 assembly and loading is missing.
One might thus expect that the unoccupied amphiphilic
peptide binding groove is rendering the class II molecules
unstable and prone to aggregation (Rabinowitz et al. 1998;
Vogt et al. 1997). For this reason, it has been argued that so-
called “empty” class II molecules are not truly empty but
filled with loosely bound peptides. We thus wanted to
characterize sDQ2 molecules produced in S2 cells in more
detail.
By SDS-PAGE analysis under reducing conditions, we
observed a strong band at 50 kDa in addition to the bands of
the sDQ2 α- and β-chains. A similar type of contamination
has not been observed with other soluble HLA molecules
produced in baculovirus infected Sf9 insect cells, nor in the
wild type EBV-DQ2 produced by EBV-transformed B cells.
This contaminating protein was identified as the D.
melanogaster-derived DCB-45 protein and our findings
suggest a tight interaction between sDQ2 and DCB-45. The
complex does not dissociate under the condition of high pH
and high salt concentrations used for elution from the
Fig. 5 Peptide binding specificity of sDQ2 compared to EBV-DQ2.
sDQ2 (1 μM) and EBV-DQ2 (0.3 μM) was incubated with the
radioactively labeled indicator peptide P198 (KPLLIIAEDVEGEY)
and titrations of competitor peptides. The HLA-DQ2-α-I gliadin
epitope (LQPFPQPELPY) and analogs were used. The bars show the
IC50 values (in μM). The relative binding capacity for each peptide is
given and was calculated as the ratio of the IC50 of the reference
peptide P198 to the IC50 of the test peptide. The Z in the amino acid
sequence denotes norvaline, X denotes 4-hydroxyproline. All peptides
marked with an asterisk (*) have an IC50 value higher than 167 μM
and the exact value could not be determined
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antibody affinity column (pH 11.5 and 2 M Tris), and
treatment at low pH resulted in precipitation rather in
dissociation of the two proteins. In contrast, the sDQ2
molecules found in the large aggregates (>600 kDa) appar-
ently are not associated with DCB-45, suggesting that sDQ2
is unstable in the absence of DCB-45. The sDQ2/DCB-45
interaction thus likely explains the observed high expression
yield of peptide-receptive sDQ2.
DCB-45 is a highly acidic protein (pI 4.27) and HLA-
DQ2 has a strong preference for binding negatively charged
residues in several of its anchor positions (Kim et al. 2004).
We therefore investigated whether the sDQ2/DCB-45 bind-
ing is also involving the peptide binding groove of sDQ2.
The characterization of such a strong interaction could be
helpful to design new lead structures for high affinity HLA-
DQ2 blockers. Such reagents have been discussed in the
treatment of celiac disease to inhibit HLA-DQ2-rectricted
presentation of gluten derived epitopes (Bergseng et al.
2005; Xia et al. 2006, 2007).
In the presence of HLA-DM, binding of the known
HLA-DQ2 ligand P198 to the isolated sDQ2/DCB-45
complex increased. The same effect of HLA-DM was
observed after limited proteolysis of this complex leading
to almost exclusive degradation of DCB-45 and a markedly
increase of heterodimeric sDQ2 (Fig. 2). Analysis by size
exclusion chromatography showed that this fraction was
stable. Interestingly, DCB-45-derived peptides could be
released at low pH and were found to originate from the N-
terminal 54-mer (Fig. 3). As these findings strongly
indicate a specific interaction of this region with the
sDQ2 peptide binding groove, a more detailed mapping
was performed. Using detergent-solubilized EBV-DQ2, the
pentadecapeptide HNAQFDHEAFLGPDE was found as
the best binder with an affinity similar to that of the P198
ligand. The data also suggest the sequence AQFDHEAFL
as the 9-mer core region with negative charges in positions
P4 and P6 and a large hydrophobic residue in position P9
that are favorable for interaction with the sDQ2 peptide
binding groove. This sequence contains alanine in position
1, which is not expected to be favorable due to its small
size and the preference that HLA-DQ2 has for bulky
hydrophobic anchor residues at this position (van de Wal et
al. 1996; Vartdal et al. 1996). Notably, peptide binding to
HLA-DQ2 is characterized by contributions from anchor
residues in position 1, 4, 6, 7, and 9 (Kim et al. 2004). This
is in contrast to peptide binding to HLA-DR molecules
which has a dominant contribution of the P1 anchor
(Jardetzky et al. 1990; Stern et al. 1994). Given that the
peptide AQFDHEAFL has optimal anchor residues at
positions P4 (D), P6 (E), and P9 (L), an alanine residue at
P1 with no repulsive effect may well be compatible with
the high affinity binding of this ligand. Moreover, in silico
searching for possible binding registers based on binding
studies with peptide libraries (Jüse et al., unpublished) gave
no better candidates for high affinity HLA-DQ2 ligands
within the 54-mer region. The DCB-45-derived 15-mer
HNAQFDHEAFLGPDE is a good HLA-DQ2 binder, and
we found that it is binding to HLA-DQ2 with a higher
affinity than the HLA-DQ2-α-Ι-gliadin peptide that is an
immunodominant epitope of celiac lesion derived CD4 T
cells. Work parallel to this study (Xia et al. 2007) has
demonstrated that even higher binding affinity than that of
the DCB-45-derived pentadecapeptide as well as high
proteolytic stability are required to obtain HLA-DQ2
blockers that effectively prevent activation of gliadin
reactive T cells. Several chemical modifications that
improve HLA-DQ2 binding affinity and proteolytic resis-
tance would thus be required to make the DCB-45-derived
ligand becoming an effective HLA-DQ2 blocker.
The observations presented in this paper are relevant for
anyone aiming to express MHC class II molecules in S2
cells. DCB-45 is influencing the availability of free and
functional peptide binding site of recombinant sDQ2,
resulting in a decreased peptide binding capacity of the
expressed molecules. Our findings illustrate that de novo
interaction of recombinant MHC class II molecules with
proteins derived from the expression system can occur.
Prior to large scale use in peptide binding studies, such
MHC class II molecules should be carefully characterized
and compared with respect to peptide binding specificity
and capacity to the wild type molecules, which are, e.g.,
purified from Epstein–Barr virus-transformed B lympho-
blastoid cell lines.
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